Chloroquine Phosphate

Chloroquine phosphate is a synthetic 4-aminoquinoline compound developed originally as an antimalarial agent for human medicine that has found limited but important applications in veterinary medicine, including extra-label use in cats for the treatment of certain protozoal infections and investigational use in immune-mediated and neoplastic conditions. No veterinary-specific formulation of chloroquine exists, and all feline use involves human-labeled products prescribed under the guidance of the Animal Medicinal Drug Use Clarification Act (AMDUCA), which permits veterinarians to prescribe FDA-approved human drugs for animals when no approved veterinary alternative is available. The drug's narrow therapeutic index in cats demands careful dosing, vigilant monitoring, and a clear understanding of the risks involved in its administration to feline patients.

Chloroquine was first synthesized in 1934 by Hans Andersag at Bayer and subsequently developed for widespread antimalarial use during World War II. Its pharmacological properties extend well beyond antiprotozoal activity, encompassing anti-inflammatory, immunomodulatory, and lysosomotropic effects that have generated interest in its application across diverse disease processes. In human medicine, chloroquine and its derivative hydroxychloroquine are used in the management of malaria, rheumatoid arthritis, systemic lupus erythematosus, and various other conditions. Veterinary exploration of chloroquine's therapeutic potential in cats has been more limited, driven by the relatively uncommon occurrence of susceptible protozoal diseases in domestic feline populations and the availability of alternative agents with wider safety margins for many conditions.

The chemical structure of chloroquine phosphate consists of the chloroquine base combined with phosphoric acid to form a water-soluble salt suitable for oral administration. Chloroquine phosphate tablets contain either 250 milligrams or 500 milligrams of the salt, which correspond to approximately 150 milligrams and 300 milligrams of chloroquine base, respectively. This distinction between salt and base weights is critically important in veterinary dosing calculations, as confusion between the two can result in significant underdosing or overdosing. Veterinary references may express chloroquine doses in terms of either the phosphate salt or the base, and practitioners must verify which form is being referenced before calculating the dose for a feline patient.

The decision to use chloroquine phosphate in a cat is not undertaken lightly and typically reflects a clinical situation where the benefits of treatment are judged to outweigh the substantial risks associated with the drug's toxicity profile. Cats present unique pharmacological challenges for chloroquine administration due to their relatively small body size, species-specific metabolic characteristics, and the difficulty of accurately dosing tablets formulated for adult human patients. The smallest commercially available tablet of 250 milligrams of chloroquine phosphate contains a dose that far exceeds the requirements for most cats, necessitating precise compounding or tablet splitting that introduces additional dosing variability. These practical challenges, combined with the drug's inherent toxicity, make chloroquine a medication that should only be prescribed and monitored by veterinarians with specific experience in its feline application.

The primary veterinary indication for chloroquine phosphate in cats involves the treatment of protozoal infections, particularly those caused by organisms susceptible to the drug's antiprotozoal mechanisms. Hepatozoonosis, caused by Hepatozoon felis or Hepatozoon canis, is a tick-transmitted protozoal disease that has been documented in cats in various regions worldwide, and chloroquine has been used as a component of treatment protocols for this infection. While hepatozoonosis is more commonly recognized in dogs, feline cases occur and may present with fever, lethargy, anemia, and muscle pain. The efficacy of chloroquine against Hepatozoon species in cats is based primarily on extrapolation from canine and human experience rather than large-scale feline clinical trials, reflecting the rare nature of the condition in domestic cats.

Investigational and empirical use of chloroquine in cats has been explored for other protozoal conditions, including as an adjunctive agent in the management of certain blood-borne parasitic infections. The drug's ability to concentrate within acidic intracellular compartments, particularly lysosomes, gives it theoretical activity against intracellular protozoa that replicate within host cells. However, the clinical evidence supporting chloroquine's efficacy against most feline protozoal infections remains limited, and veterinary specialists in infectious disease may consider it only when first-line agents have failed or are unavailable. For conditions such as cytauxzoonosis, caused by Cytauxzoon felis, other antiprotozoal agents including atovaquone combined with azithromycin have largely supplanted older treatment approaches, though chloroquine may appear in historical treatment references.

Beyond its antiprotozoal activity, chloroquine possesses immunomodulatory properties that have prompted investigation into its potential role in managing immune-mediated diseases in cats. The drug inhibits antigen processing and presentation by raising the pH of intracellular compartments, reduces the production of certain pro-inflammatory cytokines including tumor necrosis factor-alpha and interleukin-6, and modulates toll-like receptor signaling pathways. These mechanisms have established hydroxychloroquine as a cornerstone treatment for systemic lupus erythematosus and other autoimmune conditions in humans, and veterinary researchers have explored whether similar benefits might apply to feline immune-mediated diseases. However, the toxicity concerns in cats and the availability of better-studied immunosuppressive agents such as corticosteroids, cyclosporine, and chlorambucil have limited widespread adoption of chloroquine for immunomodulatory purposes in feline medicine.

Emerging research has examined the lysosomotropic properties of chloroquine in the context of feline oncology, particularly its ability to inhibit autophagy, a cellular survival mechanism that some cancer cells exploit to resist chemotherapy-induced cell death. By blocking the final stages of autophagy through inhibition of lysosomal function, chloroquine may theoretically sensitize certain tumor cells to concurrent chemotherapeutic agents. While this concept has progressed to clinical trials in human oncology, its application in feline cancer treatment remains largely experimental and is not part of standard veterinary oncological protocols. Any use of chloroquine as an autophagy inhibitor in feline cancer patients would occur within the framework of clinical research or as a carefully considered last-resort adjunctive therapy.

Dosing of chloroquine phosphate in cats requires meticulous calculation and the recognition that published dosing guidelines are limited and largely extrapolated from canine and human protocols. The commonly referenced oral dose for cats ranges from approximately 1 to 2 milligrams per kilogram of chloroquine base administered daily or every other day, depending on the condition being treated and the prescribing veterinarian's assessment of the individual patient's risk-benefit profile. It is essential to distinguish between doses expressed as chloroquine base versus chloroquine phosphate salt, as the salt contains approximately sixty percent chloroquine base by weight. A dose intended as 2 milligrams per kilogram of base would correspond to roughly 3.3 milligrams per kilogram of the phosphate salt, and errors in this conversion can lead to significant dosing mistakes with potentially fatal consequences.

The practical challenge of dosing chloroquine for cats stems from the human-labeled tablet formulations available. The smallest standard tablet of 250 milligrams of chloroquine phosphate (equivalent to approximately 150 milligrams of base) vastly exceeds the dose required for a typical four to five kilogram cat. Compounding pharmacies can prepare chloroquine in appropriate concentrations as oral suspensions or smaller capsules tailored to feline doses, and this approach is strongly preferred over attempting to split or crush commercially available tablets. Compounded preparations allow for more precise dosing and can be flavored to improve palatability, though the stability and bioavailability of compounded formulations should be verified with the compounding pharmacy. If tablet splitting is unavoidable, the use of a precision pill cutter and careful weighing on a milligram-scale balance is advisable.

Treatment duration with chloroquine phosphate varies considerably based on the clinical indication and the patient's response. For protozoal infections, treatment courses may range from several weeks to months, with periodic reassessment of clinical status, laboratory parameters, and the need for continued therapy. Some protozoal conditions, particularly hepatozoonosis, may require extended or intermittent treatment protocols as the organisms can be difficult to fully eradicate. The prescribing veterinarian establishes the treatment timeline and adjusts it based on clinical response, monitoring results, and the emergence of any adverse effects that might necessitate dose reduction or discontinuation.

Administration of chloroquine to cats should ideally occur with food to reduce gastrointestinal irritation, which is one of the most common dose-limiting side effects. The tablets or compounded preparations are given orally, and the cat should be observed after dosing to ensure the medication is swallowed and not spit out or hidden in the mouth. If a cat vomits within thirty minutes of receiving chloroquine, the veterinarian should be consulted regarding whether the dose should be repeated, as both the risk of underdosing from lost medication and the risk of overdosing from a repeat dose must be weighed. Consistent timing of daily doses helps maintain steady drug levels and simplifies the owner's administration routine.

Missed doses should be addressed according to the prescribing veterinarian's specific guidance for the individual patient. As a general principle, if a dose is missed and remembered within a few hours of the scheduled time, it may be given at that point. If the missed dose is not discovered until close to the time of the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed without doubling up. Chloroquine's relatively long half-life provides some buffer against the pharmacological impact of a single missed dose, but consistent adherence to the prescribed regimen is important for treatment efficacy. Owners should maintain a dosing log, particularly during the early phases of treatment, to track administration and any observed adverse effects.

Chloroquine's antiprotozoal mechanism centers on its ability to accumulate within the acidic food vacuoles of susceptible organisms, where it interferes with the parasite's ability to detoxify the heme byproducts of hemoglobin digestion. In malarial parasites, which serve as the best-studied model for chloroquine's antiprotozoal activity, the organism ingests host hemoglobin and degrades it within its digestive vacuole to obtain amino acids for growth. This degradation process releases free heme, which is toxic to the parasite. The organism normally detoxifies free heme by polymerizing it into hemozoin, an insoluble crystalline pigment. Chloroquine binds to free heme and inhibits its polymerization into hemozoin, causing the accumulation of toxic heme complexes that damage the parasite's membranes and ultimately kill it. While this mechanism has been most thoroughly characterized in Plasmodium species, analogous processes may contribute to chloroquine's activity against other protozoal organisms that process heme during their life cycles.

The lysosomotropic properties of chloroquine are fundamental to both its therapeutic effects and its toxicity profile. Chloroquine is a weak diprotic base that exists in an uncharged form at neutral pH, allowing it to diffuse freely across cell membranes. Once inside acidic intracellular compartments such as lysosomes and endosomes, chloroquine becomes protonated and trapped, accumulating to concentrations hundreds of times higher than those in the extracellular fluid. This massive intracellular accumulation raises the pH of these compartments, disrupting the function of acid-dependent enzymes and interfering with numerous cellular processes including protein degradation, receptor recycling, and antigen processing. The lysosomotropic effect is the basis for chloroquine's immunomodulatory actions and its ability to inhibit autophagy.

The immunomodulatory mechanisms of chloroquine involve multiple interconnected pathways that collectively dampen inflammatory and immune responses. By raising the pH of endosomal and lysosomal compartments in antigen-presenting cells, chloroquine impairs the processing of protein antigens and their loading onto major histocompatibility complex class II molecules, reducing T-cell activation. Chloroquine also inhibits toll-like receptor signaling, particularly TLR7 and TLR9, which recognize nucleic acid patterns and play roles in both antimicrobial immunity and autoimmune pathology. Additionally, the drug reduces the secretion of pro-inflammatory cytokines including tumor necrosis factor-alpha, interleukin-1, and interleukin-6, contributing to its anti-inflammatory effects. These immunomodulatory actions occur at drug concentrations achievable with therapeutic dosing, making them clinically relevant considerations in the overall pharmacological profile.

Chloroquine's pharmacokinetic behavior in cats has not been extensively characterized through species-specific studies, and much of what is known derives from extrapolation from human and canine pharmacokinetic data. In humans, chloroquine is rapidly and almost completely absorbed following oral administration, with peak plasma concentrations achieved within one to two hours. The drug has an extremely large volume of distribution, reflecting extensive tissue binding, particularly in melanin-containing tissues such as the retinal pigment epithelium, skin, and hair follicles. Hepatic metabolism via cytochrome P450 enzymes, primarily CYP2C8 and CYP3A4, produces the active metabolite desethylchloroquine, which contributes to the overall pharmacological effect. The elimination half-life in humans is remarkably long, ranging from one to two months, and while the half-life in cats is not precisely established, prolonged tissue retention is expected and has implications for both the duration of therapeutic effect and the persistence of any toxic effects.

The side effect profile of chloroquine phosphate in cats is a primary concern that governs all decisions regarding its use and demands continuous vigilance throughout the treatment period. Gastrointestinal disturbances are the most frequently encountered adverse effects and often the earliest to manifest. Anorexia, nausea, vomiting, and diarrhea may occur at therapeutic doses and can range from mild and manageable with supportive measures to severe enough to necessitate dose reduction or treatment discontinuation. Cats may refuse food after receiving chloroquine, and the resulting decreased caloric intake can compound the debilitation already caused by the underlying disease being treated. Administering the medication with food and dividing the daily dose into smaller, more frequent administrations may help mitigate gastrointestinal side effects, though these strategies should be implemented under veterinary guidance.

Retinal toxicity is one of the most serious and potentially irreversible adverse effects associated with chloroquine use. Chloroquine accumulates in melanin-containing tissues, and the retinal pigment epithelium contains high concentrations of melanin that avidly bind the drug. Chronic chloroquine exposure causes progressive destruction of retinal photoreceptors and the retinal pigment epithelium, leading to a characteristic pattern of retinal damage known in human medicine as bull's-eye maculopathy. In cats, retinal degeneration may manifest as progressive visual impairment that can progress to blindness. The risk of retinal toxicity increases with cumulative dose and duration of treatment, and the damage, once established, is generally irreversible even after discontinuation of the drug. Ophthalmologic monitoring, including fundoscopic examination, is recommended for cats receiving chloroquine therapy of any significant duration.

Cardiotoxicity represents another life-threatening potential adverse effect of chloroquine in cats. Chloroquine affects cardiac ion channels, particularly the human ether-a-go-go-related gene (hERG) potassium channels, which can prolong the QT interval on electrocardiography and predispose to potentially fatal cardiac arrhythmias including ventricular tachycardia and torsades de pointes. In acute overdose situations, chloroquine can cause rapid cardiovascular collapse with hypotension, conduction abnormalities, and cardiac arrest. The cardiovascular effects may be more pronounced in cats with pre-existing cardiac disease, electrolyte imbalances, or concurrent administration of other drugs that prolong the QT interval. Electrocardiographic monitoring is advisable during chloroquine therapy, particularly at the initiation of treatment and after any dose adjustments.

Neurotoxicity and neuromuscular effects have been reported with chloroquine use and may present as muscle weakness, tremors, ataxia, or behavioral changes in affected cats. The mechanisms underlying these effects likely involve chloroquine's accumulation in neural tissue and its disruption of lysosomal function within neurons and muscle cells. Seizures have been documented in cases of chloroquine overdose, and even at therapeutic doses, some cats may exhibit subtle neurological signs that require careful observation to detect. Hepatotoxicity is an additional concern, as chloroquine undergoes hepatic metabolism and can cause elevations in liver enzymes and, in severe cases, hepatocellular damage. Periodic monitoring of serum chemistry panels, including liver enzyme levels, helps detect hepatic effects before they progress to clinically significant liver injury.

Hematological adverse effects, while less common than gastrointestinal symptoms, include bone marrow suppression manifesting as leukopenia, thrombocytopenia, or anemia. These effects may be related to chloroquine's general cytotoxic properties at higher concentrations and its interference with cellular processes in rapidly dividing bone marrow precursor cells. Cats receiving chloroquine should have periodic complete blood count monitoring to detect hematological changes early. Agranulocytosis, though rare, has been reported in human patients receiving chloroquine and represents a potentially serious complication if it occurs in feline patients, as the resulting immunosuppression increases susceptibility to secondary infections.

Chloroquine phosphate participates in numerous drug interactions that must be carefully evaluated before initiating therapy in feline patients, as many of these interactions can potentiate toxicity or reduce therapeutic efficacy. Concurrent administration of other QT-prolonging medications represents one of the most dangerous potential interactions with chloroquine. Drugs including certain fluoroquinolone antibiotics, macrolide antibiotics such as azithromycin and erythromycin, antiarrhythmic agents, and some antiemetics can additively or synergistically prolong the QT interval when combined with chloroquine, significantly increasing the risk of fatal cardiac arrhythmias. Veterinarians must review the complete medication list of any cat being considered for chloroquine therapy and assess the cumulative risk of QT prolongation before proceeding.

Interactions with hepatically metabolized drugs are relevant given chloroquine's dependence on cytochrome P450 enzymes for its own metabolism. Drugs that inhibit CYP2C8 or CYP3A4 can slow chloroquine metabolism, leading to increased plasma concentrations and heightened toxicity risk. Conversely, CYP enzyme inducers may accelerate chloroquine metabolism and potentially reduce its therapeutic efficacy. While feline-specific CYP450 enzyme characterization is less complete than in humans, the general principle of metabolic drug interactions applies and should inform prescribing decisions. Cimetidine, ketoconazole, and other known CYP inhibitors commonly used in feline medicine should be used with caution or avoided in cats receiving chloroquine.

Antacids, kaolin, and other gastrointestinal adsorbents can reduce the oral absorption of chloroquine when administered concurrently or in close temporal proximity. These agents bind chloroquine in the gastrointestinal lumen, reducing the amount available for absorption and potentially resulting in subtherapeutic drug levels. If gastrointestinal protectants or antacids are needed for a cat receiving chloroquine, they should be administered at least two to four hours before or after the chloroquine dose to minimize this interaction. Sucralfate, which is sometimes used in feline medicine for gastrointestinal ulceration, also has the potential to bind concurrently administered medications and should follow the same temporal separation guideline.

The combination of chloroquine with other antiparasitic agents requires careful consideration of overlapping toxicity profiles. When chloroquine is used alongside other antiprotozoal drugs as part of a combination treatment protocol, the potential for additive hepatotoxicity, nephrotoxicity, or hematological suppression must be assessed. Some combination protocols have been used in veterinary medicine with appropriate monitoring, but the decision to combine antiparasitic agents should be made by veterinarians experienced in managing the specific protozoal infection being treated. Concurrent use of chloroquine with ampicillin has been noted to reduce ampicillin bioavailability in some species, which may be relevant if antibiotic coverage is needed during chloroquine therapy.

Chloroquine phosphate is contraindicated in cats with known hypersensitivity to chloroquine, hydroxychloroquine, or any component of the formulation. While documented chloroquine hypersensitivity in cats is exceedingly rare due to the limited use of the drug in feline patients, any cat that has previously experienced an adverse reaction to a 4-aminoquinoline compound should not receive chloroquine. Cross-reactivity between chloroquine and hydroxychloroquine is expected given their close structural relationship, and cats with documented reactions to either agent should be considered allergic to both.

Pre-existing retinal disease or visual impairment represents a significant contraindication or at minimum a strong precaution for chloroquine use in cats. Given the drug's well-established retinal toxicity, administering chloroquine to a cat with compromised retinal function risks accelerating visual loss. A thorough ophthalmic examination, including fundoscopy, should be performed before initiating chloroquine therapy to establish a baseline retinal status and to identify any pre-existing retinal pathology that would increase the risk of drug-induced damage. Cats with taurine-deficiency retinopathy, progressive retinal atrophy, or other forms of retinal degeneration should not receive chloroquine unless the life-threatening nature of the condition being treated clearly justifies the additional risk to vision.

Hepatic insufficiency alters chloroquine metabolism and increases the risk of drug accumulation and toxicity. Cats with known liver disease, elevated liver enzymes, or clinical signs suggestive of hepatic dysfunction require particularly careful evaluation before chloroquine is prescribed. If the decision is made to proceed with treatment in a cat with compromised hepatic function, dose reduction and more frequent monitoring of liver parameters are essential. Similarly, renal impairment may affect the elimination of chloroquine metabolites and necessitate dosing adjustments. Although hepatic metabolism is the primary route of chloroquine biotransformation, renal excretion contributes to the elimination of both parent drug and metabolites, and reduced renal function can lead to accumulation.

Pregnancy and lactation represent additional precautions for chloroquine use in cats. Chloroquine crosses the placental barrier and is excreted in milk. In human medicine, chloroquine has been used during pregnancy for malaria treatment when the benefits justify the risks, but teratogenic effects have been demonstrated in some animal studies at high doses. In breeding queens, the potential risks to developing kittens must be weighed against the therapeutic necessity of treatment. Similarly, nursing kittens could be exposed to chloroquine through milk ingestion, and the effects of such exposure on neonatal development are not well characterized. Unless the clinical situation is dire, alternative treatments should be sought for pregnant or lactating cats.

Cats with pre-existing cardiac conduction abnormalities, cardiomyopathy, or electrolyte imbalances face increased risk of chloroquine-induced cardiac toxicity. Hypokalemia, hypomagnesemia, and hypocalcemia can all lower the threshold for cardiac arrhythmias in the setting of chloroquine use and should be corrected before therapy is initiated. A baseline electrocardiogram is advisable for any cat being considered for chloroquine treatment, and cats with identified conduction abnormalities may require alternative therapeutic approaches. The concurrent administration of other cardiac-active medications, including beta-blockers, calcium channel blockers, and cardiac glycosides, requires careful evaluation of potential additive effects on cardiac conduction and rhythm.

Comprehensive monitoring is an indispensable component of safe chloroquine phosphate therapy in cats, and the frequency and scope of monitoring should reflect the duration of treatment and the individual patient's risk factors. Before initiating chloroquine therapy, baseline laboratory evaluation should include a complete blood count, serum chemistry panel with particular attention to hepatic and renal parameters, and electrolyte assessment. An electrocardiogram provides baseline cardiac conduction data against which subsequent monitoring can be compared. Ophthalmic examination including fundoscopy establishes baseline retinal status. These pretreatment assessments serve the dual purpose of identifying contraindications to therapy and providing reference values for detecting drug-induced changes during the course of treatment.

During the initial phase of chloroquine therapy, typically the first two to four weeks, monitoring should be conducted at relatively frequent intervals as this period carries the highest risk for acute adverse reactions and allows for early detection of dose-dependent toxicity. Serum chemistry panels and complete blood counts should be performed weekly during this early phase, with particular attention to liver enzyme trends, renal function indicators, and hematological parameters. Clinical assessment at each monitoring visit should include evaluation of body weight, hydration status, appetite, gastrointestinal function, and neurological status. Any cat showing signs of significant toxicity during this period requires immediate reassessment of the risk-benefit ratio of continued treatment.

For cats continuing chloroquine therapy beyond the initial phase, monitoring intervals may be extended to biweekly or monthly, depending on the stability of clinical and laboratory parameters. Periodic ophthalmologic examinations remain essential throughout the treatment course and for some time after discontinuation, as retinal toxicity can manifest or progress even after the drug has been stopped due to its prolonged tissue retention. Electrocardiographic monitoring should be performed at regular intervals and whenever the cat's clinical status changes or new medications are introduced. Owner education about the signs of potential toxicity, including changes in appetite, vomiting, behavioral changes, visual impairment, and weakness, enables early reporting of problems between scheduled veterinary visits.

The decision to continue, adjust, or discontinue chloroquine therapy is guided by the ongoing assessment of treatment response weighed against the cumulative risk of toxicity. For protozoal infections, periodic evaluation of parasitemia or other disease markers informs whether the infection is responding to treatment and whether continued therapy is justified. If clinical improvement is not observed within a reasonable timeframe, the veterinarian should reconsider the diagnosis, evaluate for drug resistance, and explore alternative treatment options rather than prolonging exposure to a potentially toxic medication. When treatment is completed or discontinued, a tapering schedule may be considered depending on the clinical situation, though the drug's long tissue half-life means that abrupt discontinuation does not carry the same risks of rebound that might be seen with rapidly cleared medications.

Documentation of all aspects of chloroquine therapy is important for ongoing patient management and for contributing to the limited veterinary knowledge base regarding this drug's use in cats. Detailed records of dosing, monitoring results, adverse effects, and clinical outcomes provide valuable information for future treatment decisions for the individual patient and may contribute to case reports or clinical series that advance veterinary understanding of chloroquine's role in feline medicine. Veterinarians prescribing chloroquine to cats should be prepared to report significant adverse events through the appropriate veterinary pharmacovigilance channels, contributing to the collective knowledge that protects future patients.

Chloroquine overdose in cats constitutes a medical emergency requiring immediate and aggressive intervention, as the margin between therapeutic and lethal doses is dangerously narrow. In human medicine, chloroquine is recognized as one of the most dangerous drugs in acute overdose, with reports of fatalities occurring at doses only three to four times the therapeutic level. Given the small body size of cats and the large tablet strengths available, accidental ingestion of even a single human-strength tablet by a cat could deliver a massive and potentially fatal overdose. The rapid absorption of chloroquine from the gastrointestinal tract means that clinical deterioration can occur within one to three hours of ingestion, leaving a narrow window for intervention.

The clinical presentation of acute chloroquine toxicity in cats may include rapid onset of cardiovascular collapse with severe hypotension, bradycardia or tachycardia, QT prolongation progressing to ventricular arrhythmias, and cardiac arrest. Neurological signs including seizures, obtundation, and coma may develop concurrently with or independently of cardiovascular manifestations. Severe hypokalemia often accompanies acute toxicity due to intracellular potassium shifts driven by chloroquine's membrane effects and may exacerbate cardiac arrhythmias. Respiratory depression can occur secondary to central nervous system depression or as a consequence of cardiovascular failure, and affected cats may require mechanical ventilation support.

Immediate decontamination measures should be undertaken when a cat is known to have ingested chloroquine and presents within one to two hours of exposure. Induction of emesis may be attempted if the cat is fully conscious and alert, though the rapid onset of central nervous system depression with chloroquine overdose means that emesis may become contraindicated quickly as the cat's mental status deteriorates. Gastric lavage under general anesthesia may be considered in obtunded patients when the ingestion is recent. Activated charcoal administered orally reduces further absorption and may be beneficial if given early, as chloroquine adsorbs to activated charcoal effectively. Multiple-dose activated charcoal has been recommended in human chloroquine overdose protocols to interrupt enterohepatic recirculation.

Cardiovascular support is the cornerstone of managing severe chloroquine toxicity. Intravenous fluid therapy is essential for supporting blood pressure and perfusion. Based on human protocols, early administration of intravenous diazepam has been shown to improve survival in chloroquine poisoning, likely through its anticonvulsant, anxiolytic, and possible membrane-stabilizing effects. Epinephrine infusion may be necessary to support blood pressure and cardiac output in cases of severe cardiovascular depression. Aggressive potassium replacement addresses the hypokalemia that potentiates cardiac arrhythmias. Mechanical ventilation may be required if respiratory depression develops. Continuous electrocardiographic monitoring is essential, and antiarrhythmic therapy should be guided by the specific rhythm disturbances present, with recognition that some standard antiarrhythmic agents may compound the QT-prolonging effects of chloroquine.

The prognosis for chloroquine overdose in cats depends on the dose ingested, the time elapsed before treatment, and the aggressiveness of supportive care provided. Cats that receive decontamination and cardiovascular support within the first hour of exposure have the best chance of survival, while those presenting in cardiovascular collapse face a guarded to grave prognosis. Survivors of acute chloroquine toxicity should be monitored for delayed complications including hepatic injury, retinal damage, and neuromuscular weakness that may become apparent in the days following the acute event. Prevention of accidental feline exposure through secure storage of chloroquine tablets away from all animals is critically important, and cat owners whose households contain chloroquine for human use should be specifically counseled about the extreme danger this medication poses to their pets.